Aura Biosciences, Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

AURA$7.66+16.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	June 30, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$107,367	$31,693
Marketable securities	69,944	119,401
Prepaid expenses and other current assets	6,647	9,529
Total current assets	183,958	160,623
Restricted cash and deposits	768	768
Right-of-use assets - operating lease	16,622	17,379
Other long-term assets	185	518
Property and equipment, net	2,864	3,215
Total Assets	$204,397	$182,503
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	1,286	2,304
Short-term operating lease liability	3,196	3,149
Accrued expenses and other current liabilities	10,370	9,460
Total current liabilities	14,852	14,913
Long-term operating lease liability	14,916	15,620
Total Liabilities	29,768	30,533
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at June 30, 2025 and December 31, 2024, and 62,071,050 and 49,998,279 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	—	—
Additional paid-in capital	603,333	525,934
Accumulated deficit	(428,729)	(374,227)
Accumulated other comprehensive income	25	263
Total Stockholders’ Equity	174,629	151,970
Total Liabilities and Stockholders’ Equity	$204,397	$182,503

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.